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ABSTRACT
Objectives: Later weekday of surgery for oesophageal
cancer seems to increase 5-year mortality, but the
mechanisms are unclear. We hypothesised that early
postoperative reoperations and mortality might explain
this association, since reoperation after oesophagectomy
decreases long-term prognosis, and later weekday of
elective surgery increases 30-day mortality.
Design: This was a population-based cohort study
during the study period 1987–2014.
Setting: All Swedish hospitals conducting elective
surgery for oesophageal cancer in Sweden.
Participants: Included were 1748 patients, representing
almost all (98%) patients who underwent elective surgery
for oesophageal cancer in Sweden during 1987–2010,
with follow-up until 2014.
Primary and secondary outcome measures: The
risk of reoperation or mortality within 30 days of
oesophageal cancer surgery was assessed in relation to
weekday of surgery by calculating ORs with 95% CIs
using multivariable logistic regression. ORs were
adjusted for age, comorbidity, tumour stage, histology,
neoadjuvant therapy and surgeon volume.
Results: Surgery Wednesday to Friday did not increase
the risk of reoperation or mortality compared with
surgery Monday to Tuesday (OR=0.99, 95% CI 0.75 to
1.31). A decreased point estimate of reoperation
(OR=0.88, 95% CI 0.64 to 1.21) was counteracted by an
increased point estimate of mortality (OR=1.28, 95% CI
0.83 to 1.99). ORs did not increase from Monday to
Friday when each weekday was analysed separately.
There was no association between weekday of surgery
and reoperation specifically for anastomotic leak,
laparotomy or wound infection. Stratification for surgeon
volume did not reveal any clear associations between
weekday of surgery and risk of 30-day reoperation or
mortality.
Conclusions:Weekday of oesophageal cancer surgery
does not seem to influence the risk of reoperation or
mortality within 30 days of surgery, and thus cannot
explain the association between weekday of surgery and
long-term prognosis.
INTRODUCTION
In a recent Swedish cohort study, we found
increased 5-year all-cause and disease-speciﬁc
5-year mortality following surgery for
oesophageal cancer later in the week com-
pared with earlier weekdays, and the associ-
ation seemed to increase for each weekday.1
The mechanism explaining these associa-
tions remains to be identiﬁed. Another study
from our group revealed that patients who
require reoperation within 30 days of
oesophageal cancer surgery are at an
increased risk of all-cause and disease-speciﬁc
5-year mortality, also after excluding mortal-
ity occurring within the initial 3 months of
surgery.2 Moreover, later weekday of surgery
for various elective procedures has been
shown to increase the risk of severe post-
operative complications, including 30-day
mortality.3 4 Therefore, we hypothesised that
occurrence of early and severe postoperative
complications requiring reoperation or
resulting in mortality explains the association
between weekday of surgery and long-term
prognosis in oesophageal cancer. This
hypothesis was tested in a nationwide
Swedish cohort study.
METHODS
Design
This was a nationwide Swedish population-
based cohort study conducted between 1987
and 2010. Earlier versions of this cohort have
been published elsewhere.1 5–7 The study
exposure was the day of the week on which
the operation was conducted and the study
outcome was reoperations or mortality
Strengths and limitations of this study
▪ Large and population-based study with high
participation rate.
▪ Accurate assessment of the exposure, outcomes
and confounders.
▪ Complete follow-up.
▪ Competing events.
▪ Retrospective data collection.
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occurring within 30 days of the oesophagectomy. By
including both these outcomes as the main outcome, we
avoided errors from competing risks from the fact that
those who died within 30 days of surgery could not be
recorded with reoperations. The participating patients
represented 98% of all patients with oesophageal cancer
who underwent surgery in Sweden between 1 January
1987 and 31 December 2010. Eligible patients were iden-
tiﬁed from national Swedish healthcare registers.
Clinical data were extracted from medical records,
retrieved through our Swedish network of clinicians,
established in the mid-1990s as part of a prospective and
nationwide case–control study.8 Linkages of data from
individuals between registers and the identiﬁcation of
their medical records were enabled by the personal
identity number, an individual 10-digit identiﬁer
assigned to each Swedish resident on birth or immigra-
tion.9 The study was approved by the Ethical Review
Board in Stockholm, Sweden.
Registry data
The Swedish Cancer Registry was used to identify all
patients in Sweden with oesophageal cancer, repre-
sented by the diagnosis codes 150.0, 150.8 or 150.9
according to the seventh version of the International
Classiﬁcation of Diseases. This register records all cancer
diagnoses in Sweden since 1958, and has 98% nation-
wide coverage of oesophageal cancer.10 11
The Swedish Patient Registry provided data on oeso-
phagectomy, comorbidities and hospital admittances.
This register records all surgical procedures and diagno-
ses within in-hospital care in Sweden since 1987.12 The
positive predictive value for the recording of oesopha-
geal cancer surgery in this register is 99.6% according to
a validation study.13
The Swedish Causes of Death Registry provided causes
and dates of death. This register is nationwide since
1961 and highly complete.
Medical records data
The medical records of all participating patients were
continuously collected from the operating hospitals,
including surgical charts and pathological reviews of the
resected specimens. On the basis of this data collection,
we assessed weekday of oesophagectomy; comorbidity;
tumour stage, location and histology; neoadjuvant
therapy; surgery; and annual surgeon volume of oeso-
phagectomies. The reviewers of the medical records
were kept blinded from the study outcomes and ﬁlled in
a predeﬁned protocol. Comorbidity was assessed accord-
ing to the well-validated Charlson comorbidity index
scoring system.14 Tumour stage was classiﬁed according
to the TNM classiﬁcation of the Union Internationale
Contre le Cancer (UICC).15 Neoadjuvant therapy was
infrequently used in Sweden during the study period,
which was due to the limited support of such treatment
until recently.16
When used, the neoadjuvant therapy of choice was a
combination of chemotherapy and radiotherapy. The
dominating (95%) surgical procedure throughout the
study period was open transthoracic oesophageal resec-
tion with intrathoracic anastomosis. The preferred
oesophageal substitute was a pulled-up gastric tube, ana-
stomosed to the proximal oesophago in the thorax or
neck. The surgeon volume variable was created on the
basis of a previously described algorithm, where the
names of the individual surgeons were used to assign
the operation to the most experienced surgeon when-
ever more than one surgeon conducted the procedure.6
Statistical analysis
The weekday variable was analysed in two ways. First,
surgery during Monday or Tuesday was compared with
surgery during Wednesday to Friday. Second, each of the 5
weekdays was analysed as a separate category with Monday
as the reference. Potential differences in reoperation or
mortality within 30 days of surgery between exposure
groups were analysed using a multivariable logistic regres-
sion, providing ORs with 95% CIs adjusted for potential
confounding variables. Seven predeﬁned variables were
included in the multivariable model: (1) age (continuous
variable), (2) sex, (3) comorbidity (Charlson index score
0, 1 or >1), (4) tumour stage (0–I, II or III–IV), (5)
tumour histology (adenocarcinoma or squamous cell car-
cinoma), (6) neoadjuvant treatment (yes or no) and (7)
annual surgeon volume of oesophagectomies (<17 or ≥17,
median number). Furthermore, we evaluated if the effect
of weekday was modiﬁed by surgeon volume by including
an interaction term in the model. Thereafter, we derived
the ORs for weekday variable within each stratum for
surgeon volume. To manage limited missing data (2.8%),
a complete case analysis was performed. The statistical soft-
ware SAS V.9.4 (SAS Institute, Cary, North Carolina, USA)
was used for data management and statistical analysis.
RESULTS
Patients
The 1799 patients who underwent elective surgery for
oesophageal cancer during the weekdays Monday to
Friday during 1987–2010 represented 98% of all such pro-
cedures in Sweden. Of these, 51 (2.8%) were excluded
due to missing data in any of the covariates. Table 1 pre-
sents characteristics of the ﬁnal 1748 study participants,
grouped into those with and without reoperation or mor-
tality within 30 days of surgery. There were no major differ-
ences in distribution of age, sex, tumour stage, tumour
histology or use of neoadjuvant therapy comparing the
groups with and without reoperation or mortality within
30 days of surgery, while lower annual surgeon volume was
found in the group with poor short-term outcomes.
Risk of postoperative reoperation or mortality
The total rates of reoperation and mortality were 10.9%
(n=191) and 5.3% (n=93), respectively. The comparison
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of surgery later in the week (Wednesday to Friday) with
earlier in the week (Monday to Tuesday) showed no
increased risk of death or reoperation within 30 days of
surgery (adjusted OR=0.99, 95% CI 0.75 to 1.31; table 2).
When weekday of surgery was categorised into each of
the 5 weekdays, the ORs did not increase from Monday to
Friday. A slightly decreased point estimate of reoperation
(OR 0.88, 95% CI 0.64 to 1.21) following later weekday of
surgery was counteracted by an increased point estimate
of mortality (OR 1.28, 95% CI 0.83 to 1.99). There was
no increased OR of reoperation for anastomotic leak,
laparotomy or wound infection associated with later
weekday of surgery (table 2).
The analyses evaluating effect modiﬁcation by annual
surgeon volume did not reveal any statistically signiﬁcant
associations between weekday of surgery and risk of reo-
peration or mortality within 30 days of surgery for
oesophageal cancer (table 3).
DISCUSSION
This study provides no evidence of an association
between later weekday of surgery for oesophageal
cancer and risk of early postoperative reoperation or
mortality.
Table 1 Characteristics of 1748 study patients who
underwent surgical resection for oesophageal cancer in
Sweden in 1987–2010, with follow-up until 2014
No death/
reoperation
within 30 days
of surgery
Number (%)
Death/
reoperation
within
30 days
of surgery
Number (%)
Total 1490 (100) 258 (100)
Age (years): mean (SD) 65 (10) 67 (9)
Sex
Male 1110 (74) 195 (76)
Female 380 (26) 63 (24)
Charlson comorbidity index
0 870 (58) 145 (56)
1 306 (21) 57 (22)
>1 314 (21) 56 (22)
Tumour stage
0–I 357 (24) 54 (21)
II 535 (36) 104 (40)
III–IV 598 (40) 100 (39)
Tumour histology
Adenocarcinoma 675 (45) 93 (36)
Squamous
carcinoma
815 (55) 165 (64)
Neoadjuvant therapy
No 1013 (68) 170 (66)
Yes 477 (32) 88 (34)
Annual surgeon volume
<17 719 (48) 155 (60)
≥17 771 (52) 103 (40)
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Table 3 Risk of death or reoperation within 30 days of surgery for oesophageal cancer, stratified for surgeon volume
Death/reoperation
(n=258) Death (n=93)
Reoperation
(n=191)
Anastomotic
(n=34)
Laparotomy
(n=54)
Wound within
30 days (n=38)
Weekday of surgery Surgeon volume OR (95% CI)* OR (95% CI)* OR (95% CI)* OR (95% CI)* OR (95% CI)* OR (95% CI)*
Monday to Tuesday <17 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Wednesday to Friday <17 1.02 (0.72 to 1.46) 1.31 (0.78 to 2.20) 0.88 (0.58 to 1.34) 0.64 (0.19 to 2.16) 0.73 (0.36 to 1.48) 1.55 (0.69 to 3.50)
Monday to Tuesday ≥17 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Wednesday to Friday ≥17 0.94 (0.60 to 1.47) 1.22 (0.54 to 2.75) 0.87 (0.54 to 1.42) 1.26 (0.52 to 3.05) 0.79 (0.28 to 2.24) 1.25 (0.40 to 3.87)
Monday <17 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Tuesday <17 0.87 (0.54 to 1.39) 0.55 (0.25 to 1.17) 0.90 (0.52 to 1.54) 0.94 (0.23 to 3.84) 1.55 (0.65 to 3.67) 0.53 (0.15 to 1.84)
Wednesday <17 1.27 (0.78 to 2.05) 1.24 (0.63 to 2.45) 1.11 (0.63 to 1.93) 0.98 (0.22 to 4.47) 1.29 (0.50 to 3.33) 1.26 (0.43 to 3.71)
Thursday <17 0.74 (0.41 to 1.32) 0.72 (0.31 to 1.63) 0.72 (0.37 to 1.43) 0.43 (0.05 to 3.90) 0.82 (0.24 to 2.75) 1.16 (0.35 to 3.79)
Friday <17 0.58 (0.25 to 1.33) 0.92 (0.34 to 2.49) 0.32 (0.09 to 1.09) NA NA 0.96 (0.19 to 4.86)
Monday ≥17 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Tuesday ≥17 1.12 (0.67 to 1.87) 0.73 (0.27 to 2.00) 1.11 (0.64 to 1.92) 0.50 (0.17 to 1.47) 0.36 (0.11 to 1.20) 2.34 (0.47 to 11.80)
Wednesday ≥17 1.00 (0.50 to 2.02) 0.78 (0.20 to 3.05) 0.89 (0.41 to 1.94) 1.89 (0.66 to 5.39) NA 1.09 (0.10 to 12.17)
Thursday ≥17 1.06 (0.54 to 2.05) 1.10 (0.35 to 3.49) 0.92 (0.44 to 1.92) NA 1.14 (0.37 to 3.53) 2.95 (0.48 to 18.16)
Friday ≥17 0.85 (0.28 to 2.59) 1.48 (0.29 to 7.43) 1.03 (0.33 to 3.16) 0.85 (0.10 to 7.18) NA 2.89 (0.25 to 33.07)
Results presented as OR with 95% CI.
*Adjusted for age, sex, Charlson comorbidity index, tumour stage, tumour histology, neoadjuvant therapy and surgeon volume.
NA, not available.
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The strengths of the present study include the
population-based cohort design, accurate assessment of
the exposure (weekday of surgery) and outcome (post-
operative reoperation or mortality), complete follow-up,
adjustment for several potential confounding factors
and the large sample size. A weakness is that the long
study period might introduce confounding by changes
in treatment or patient selection over time. However, it
is unlikely that these changes would inﬂuence choice of
weekday of surgery, which means that these changes
would not act as confounders.17 The results should be
generalisable to other western populations of Caucasian
origin. A methodological issue is that reoperation and
mortality are competing events, since death occurring
before any potential later reoperation is not accounted
for. Therefore, the combined reoperation/mortality
outcome was selected as the main study outcome, while
the results regarding the separate reoperation outcomes
should be interpreted more cautiously. An observational
study can never rule out residual confounding, but the
risk of confounding should be counteracted by the fact
that we adjusted the risk estimates for the key potential
confounding variables. The retrospective collection of
data from medical records might introduce bias, but we
avoided such error by keeping the researchers collecting
and introducing the medical records data without being
aware of the study outcome. Finally, the occurrence of
the study outcomes was low, which resulted in limited
statistical power to detect weak differences, particularly
in stratiﬁed subgroup analyses.
To the best of our knowledge, there is no previous
study addressing weekday of oesophageal cancer surgery
in relation to reoperation or short-term mortality.
However, large cohort studies evaluating various types of
elective surgery have found an increased risk of 30-day
mortality associated with a later weekday of surgery.3 4
This was not found in this study, which might be due to
a more limited statistical power compared with studies
addressing many types of surgical procedures. However,
it is unlikely that any potentially weakly increased risk of
reoperation or short-term mortality would explain the
substantially increased long-term mortality associated
with later weekdays of oesophageal cancer surgery
reported recently.1 This suggests that the weekday effect
on long-term prognosis is due to other reasons than
poor short-term outcomes, for example, increased likeli-
hood of tumour recurrence.
Our previous ﬁndings of an association between later
weekday of surgery and increased risk of long-term mor-
tality and tumour recurrence do not seem to be
explained by worse short-term outcomes linked with
weekday of surgery.1 It is possible that the tumour dissec-
tion is negatively inﬂuenced by surgeon fatigue, while
this factor does not inﬂuence the short-term outcomes.
Another hypothesis is that surgery later in the week is
associated with a lower lymph node harvest. However, in
a separate paper from the same cohort, we have found
no prognostic role of lymph node harvest.7 A potential
role of non-radical resection in relation to weekday of
surgery and long-term survival is another hypothesis
worthy of a separate study.
In conclusion, this population-based and nationwide
Swedish cohort study found no inﬂuence of weekday of
oesophageal cancer surgery on risk of reoperations or
mortality within 30 days of surgery. Thus, poor short-
term outcomes do not seem to contribute to the associ-
ation between later weekday of oesophageal cancer
surgery and increased 5-year mortality.
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